Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03712202 · ClinicalTrials.gov registry record · Phase 2

Brentuximab Vedotin and Nivolumab in Treating Patients With Early Stage Classic Hodgkin Lymphoma

A Phase 2 study of Classic Hodgkin Lymphoma and Ann Arbor Stage IIB Hodgkin Lymphoma, sponsored by City of Hope Medical Center.

Active
Registry status
Phase 2
Development phase
155
Enrollment target
17
Study locations

NCT03712202: Active Phase 2 study of Classic Hodgkin Lymphoma and Ann Arbor Stage IIB Hodgkin Lymphoma, sponsored by City of Hope Medical Center.

NCT03712202 is a Phase 2 study of Classic Hodgkin Lymphoma and Ann Arbor Stage IIB Hodgkin Lymphoma that is active but no longer recruiting, run by City of Hope Medical Center. The registered enrollment target is 155 participants, below the 235-participant average among 9 other Classic Hodgkin Lymphoma trials with a reported enrollment target (34% lower). The trial reports 17 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03712202, a Phase 2 study of Classic Hodgkin Lymphoma and Ann Arbor Stage IIB Hodgkin Lymphoma, is active but no longer recruiting, sponsored by City of Hope Medical Center.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
155 participants
Enrollment target
17
Study locations

Study Summary

This phase II trial studies how well brentuximab vedotin and nivolumab work in treating patients with stage I-II classic Hodgkin lymphoma. Brentuximab vedotin is a monoclonal antibody, brentuximab, linked to a toxic agent called vedotin. Brentuximab attaches to CD30 positive cancer cells in a targeted way and delivers vedotin to kill them. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.

Primary Outcome

Will be estimated using the method of Kaplan and Meier.

Conditions Studied

Classic Hodgkin Lymphoma Ann Arbor Stage IIB Hodgkin Lymphoma Ann Arbor Stage IB Hodgkin Lymphoma Ann Arbor Stage II Hodgkin Lymphoma Ann Arbor Stage IIA Hodgkin Lymphoma Ann Arbor Stage I Hodgkin Lymphoma Ann Arbor Stage IA Hodgkin Lymphoma Lymphocyte-Rich Classic Hodgkin Lymphoma Ann Arbor Stage I Mixed Cellularity Classic Hodgkin Lymphoma Ann Arbor Stage I Nodular Sclerosis Classic Hodgkin Lymphoma

Interventions

  • DRUG Doxorubicin
  • BIOLOGICAL Nivolumab
  • DRUG Brentuximab Vedotin
  • DRUG Dacarbazine
  • DRUG Bleomycin

Study Locations (17)

Massachusetts

  • Beth Israel Deaconess Medical Center - Boston
  • Dana-Farber Cancer Institute - Boston
  • Massachusetts General Hospital - Charlestown

California

  • City of Hope Medical Center - Duarte
  • University of California San Diego - San Diego

Illinois

  • Northwestern University - Chicago
  • University of Chicago Comprehensive Cancer Center - Chicago

Ohio

  • Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center - Cleveland
  • Ohio State University Comprehensive Cancer Center - Columbus

Alabama

  • University of Alabama at Birmingham Cancer Center - Birmingham

Georgia

  • Emory University Hospital/Winship Cancer Institute - Atlanta

New Jersey

  • Hackensack University Medical Center - Hackensack

New York

  • NYP/Weill Cornell Medical Center - New York

Trial Details

FieldValue
Enrollment Target 155 participants
Start Date 2018-11-28
Est. Completion 2024-12-23
Phase Phase 2
City of Hope Medical Center

582 total trials

What the registry record for NCT03712202 still lists

NCT03712202 is an interventional study that assigns participants to a tested intervention. The registered 155 participants enrollment target is mid-sized for trials with a published cap, below the 235-participant average among 9 other Classic Hodgkin Lymphoma trials with a reported enrollment target (34% lower).

The record links to 10 conditions, with Classic Hodgkin Lymphoma appearing as the primary indexed condition, and to 5 interventions - of which Doxorubicin is the first listed.

NCT03712202 lists 17 locations in 12 states (Massachusetts, California, Illinois).

Frequently Asked Questions

What is clinical trial NCT03712202 about?

NCT03712202 is a clinical study titled "Brentuximab Vedotin and Nivolumab in Treating Patients With Early Stage Classic Hodgkin Lymphoma". This phase II trial studies how well brentuximab vedotin and nivolumab work in treating patients with stage I-II classic Hodgkin lymphoma. Brentuximab vedotin is a monoclonal antibody, brentuximab, linked to a toxic agent called vedotin. Brentuximab attaches to CD30 positive cancer cells in a target...

What is the current status of trial NCT03712202?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 155 participants. The study started on 2018-11-28. Estimated completion is 2024-12-23.

What conditions does trial NCT03712202 study?

This clinical trial studies the following conditions: Classic Hodgkin Lymphoma, Ann Arbor Stage IIB Hodgkin Lymphoma, Ann Arbor Stage IB Hodgkin Lymphoma, Ann Arbor Stage II Hodgkin Lymphoma, Ann Arbor Stage IIA Hodgkin Lymphoma.

What interventions are being tested in trial NCT03712202?

The interventions under investigation include: Doxorubicin (DRUG), Nivolumab (BIOLOGICAL), Brentuximab Vedotin (DRUG), Dacarbazine (DRUG), Bleomycin (DRUG).

Who is sponsoring clinical trial NCT03712202?

This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03712202 being conducted?

This trial has 17 study locations across Alabama, California, Georgia, Illinois, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Classic Hodgkin Lymphoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03712202's enrollment target sits among peer trials

155 4th of 9 higher than 6 of 9 other Classic Hodgkin Lymphoma trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Classic Hodgkin Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03223610 · 155 participants · Phase 1

    Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma

  • NCT05072483 · 155 participants

    Natural History Study of CADASIL

  • NCT05086497 · 155 participants · NA

    WBSI Guided Personalized Delivery of TTFields

  • NCT05412069 · 155 participants · NA

    Trial to Evaluate Fecobionics in Fecal Incontinence (FI) (NORMAL and ABNORMAL-FI)

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT03712202, the US trial registry maintained by the National Library of Medicine. NCT03712202 (mid enrollment · multi site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.